Evaluation of lansoprazole as a probe for assessing cytochrome P450 2C19 activity and genotype–phenotype correlation in childhood

Abstract

According to our results from a Turkish pediatric population, lansoprazole is a suitable probe drug for phenotyping CYP2C19. The CYP2C19*2 and *17 variants should be taken into consideration in predicting the clinical outcome of therapy with lansoprazole in the pediatric population.

Association of MDR1 , CYP2D6 , and CYP2C19 gene polymorphisms with prophylactic migraine treatment response

“…Aynacioglu et al, who found the PM frequency to be~1% [13], reported that the mutation responsible for the PM genotype was CYP2C19*2 and that there was no CYP2C19*3 in any of the individuals in the study. In another study, conducted by Gumus et al [24], the CYP2C19*2 frequency was 1.2% and the CYP2C19*3 variant was not detected [24]. In our study, in accordance with these studies, we found the CYP2C19*2 genotype frequency to be 19.9%, while the CYP2C19*3 and CYP2C19*4 genotypes were not detected.…”

Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine

“…Activity is then increased throughout childhood and finally reverts to levels similar to that in adults by puberty [6]. Earlier studies in pediatrics suggested little effect of CYP2C19 variation on PPIs, however, recent data have supported the role of CYP2C19 genotype in PPI therapy similar to that in adulthood [28,29]. Whether the effect of genotype on CYP2C19 is the same as in adults depends on the developmental stage of CYP2C19.…”

Pharmacokinetics of lansoprazole and its main metabolites after single intravenous doses in healthy Chinese subjects

“…For CYP2C19 phenotyping, LPZ might be a useful probe drug (Zhang et al 2011;Gumus et al 2011). The differences in the formulations and gastrointestinal situations might affect the absorption extent and rate of LPZ when using LPZ oral formulations.…”